Table 2.
Summary of the serum pharmacokinetics of secoisolariciresinol, enterodiol and enterolactone for healthy postmenopausal women (n=5) determined from serum lignan concentrations after a single-bolus oral intake of 50 mg of secoisolariciresinol-diglycoside (SDG) in a 28.8% pure and a 74.4% pure SDG extract given in a randomized double-blinded crossover design with a minimum one-week washout between.
| SDG Intake (50 mg) | Cmax (ng/mL). | Tmax (h) | Half-life (h) | Vd/F (L) | Cl/F (L) | AUCinf (h*ng/mL) | AUCinf/D¥ (h*ng/mL/mg) | Cmax/Dose¥ (ng/mL/mg) |
|---|---|---|---|---|---|---|---|---|
| Secoisolariciresinol | ||||||||
| 28.8% purity | 123 ±37 | 5.7 ±0.8 | 5.3 ±0.6 | 252 ±68 | 31 ±6 | 1065 ±252 | 40.3 ±9.5 | 4.6 ±1.4 |
| 74.4% purity | 126 ±30 | 5.6 ±1.2 | 5.5 ±0.1 | 190 ±14 | 24 ±2 | 1125 ±97 | 42.6 ±3.7 | 4.8 ±1.1 |
|
| ||||||||
| Mean (±SEM) | 124 ±23 | 5.6 ±0.7 | 5.4 ±0.3 | 224 ±37 | 28 ±3 | 1092 ±138 | 41.4 ±5.2 | 4.7 ±0.9 |
|
| ||||||||
| Enterodiol | ||||||||
| 28.8% purity | 17± 1.7 | 18.3 ±3.6 | 8.6 ±1.4 | --- | --- | 342 ±41 | --- | 0.6 ±0.1 |
| 74.4% purity | 19 ±5.0 | 16.0 ±3.3 | 11.2 ±1.6 | --- | --- | 404 ±97 | --- | 0.7 ±0.2 |
|
| ||||||||
| Mean (±SEM) | 18 ±2.3 | 17.3 ±2.4 | 9.8 ±1.1 | --- | --- | 370 ±47 | --- | 0.7 ±0.1 |
|
| ||||||||
| Enterolactone | ||||||||
| 28.8% purity | 16.8 ±3.7 | 24.0 ±0.0 | 13.9 ±1.6 | --- | --- | 487 ±90 | --- | 0.6 ±0.1 |
| 74.4% purity | 19.2 ±6.4 | 25.5 ±5.1 | 15.8 ±5.3 | --- | --- | 538 ±104 | --- | 0.7 ±0.2 |
|
| ||||||||
| Mean (±SEM) | 17.9 ±3.3 | 24.7 ±2.1 | 14.8 ±2.3 | --- | --- | 510 ±64 | --- | 0.7 ±0.1 |
¥
= Dose-adjusted based on level of SDG intake
Cmax = peak serum concentration, Tmax = time required to reach peak levels, Vd/F = volume of distribution normalized to the bioavailable fraction, CL/F = systemic clearance normalized to bioavailable fraction, AUCinf = bioavailability as apparent from area under the curve to infinity D=dose.